ArticleCancer cell2019
The Proteogenomic Landscape of Curable Prostate Cancer.
Article in Cancer cell, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 141 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
141 citing papers in PubMed, 1 synthesis or guideline pooled it, 270 citations in OpenAlex.
- Associations between genetically predicted concentrations of plasma proteins and the risk of prostate cancer.BMC cancer · 2024Pooled it
- Targeting the Androgen Receptor and Associated Cofactors in Prostate Cancer: Novel Approaches and Future Perspectives.International journal of molecular sciences · 2026Review
- Targeted proteomics for the detection of androgen receptor variants in preclinical models of castration-resistant prostate cancer.Clinical proteomics · 2026Article
- Article
- Rewriting the cancer proteome: targeting selective translation as a therapeutic frontier.The Journal of clinical investigation · 2026Article
- Plasma extracellular vesicle proteomics nominates candidate biomarkers ofCell reports. Medicine · 2026Article
- LDHA-driven lactate metabolism promotes MDSC activation and immunosuppressive microenvironment in prostate cancer.Oncogene · 2026Article
- A tissue-specific atlas of protein-protein associations enables prioritization of candidate disease genes.Nature biotechnology · 2026Article
- Identification of non-canonical peptides with moPepGen.Nature biotechnology · 2026Article
- Proteogenomics: decoding cancer in multiple dimensions.MedScience · 2026Review
- Integrated single-cell and spatial transcriptomic profiling decodes lineage plasticity and immune microenvironment remodeling in prostate cancer progression.Molecular cancer · 2026Article
- Integrative Genomic Analysis Reveals Pseudouridine Modification-Related Gene Signatures Associated With Prognosis and Therapeutic Response Patterns in Hepatocellular Carcinoma.International journal of genomics · 2026Article
- Tumor-associated M2 macrophages promote prostate cancer invasion through the M-CSF-PCLAF pathway.PloS one · 2026Article
- A panel of plasma proteins associated with venous thromboembolism in patients with prostate cancer.Cancer biomarkers : section A of Disease markers · 2025Article
- Protein disulfide isomerases regulate androgen receptor stability and promote prostate cancer cell growth and survival.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- SCAN-ACT: adoptive T cell therapy target discovery through single-cell transcriptomics.Genome medicine · 2025Article
- Extracellular vesicle heterogeneity through the lens of multiomics.Cell reports. Medicine · 2025Article
- CD13 as a potential theranostic target for prostate-specific membrane antigen-negative prostate cancer and first-in-human study of [European journal of nuclear medicine and molecular imaging · 2025Article
- Optimized graph neural network-multilayer perceptron fusion classifier for metastatic prostate cancer detection in Western and Asian populations.Asian journal of urology · 2025Article
- Identification of non-canonical peptides with moPepGen.bioRxiv : the preprint server for biology · 2025Article
81 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
28 authors at 7 institutions in 2 countries.
Funding
Abstract
DNA sequencing has identified recurrent mutations that drive the aggressiveness of prostate cancers. Surprisingly, the influence of genomic, epigenomic, and transcriptomic dysregulation on the tumor proteome remains poorly understood. We profiled the genomes, epigenomes, transcriptomes, and proteomes of 76 localized, intermediate-risk prostate cancers. We discovered that the genomic subtypes of prostate cancer converge on five proteomic subtypes, with distinct clinical trajectories. ETS fusions, the most common alteration in prostate tumors, affect different genes and pathways in the proteome and transcriptome. Globally, mRNA abundance changes explain only ∼10% of protein abundance variability. As a result, prognostic biomarkers combining genomic or epigenomic features with proteomic ones significantly outperform biomarkers comprised of a single data type.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.